Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3SBio Acquires Control of CP Guojian in $213 Million Deal

publication date: Dec 1, 2015
3SBio of Shenyang expanded its biosimilar business by raising its stake in Shanghai CP Guojian Pharma to 54%. 3SBio, which acquired 7% of Guojian last year, paid $213 million for 47% of Guojian's outstanding shares. Guojian has two biosimilar products on the market: Yisaipu, a biosimilar to Amgen's Enbrel anti-inflammatory drug, and Xenopax, a biosimilar to Biogen's Zinbryta anti-organ rejection treatment. In addition, Guojian has a portfolio of mAbs awaiting CFDA approval and a mAb manufacturing facility. More details....

Stock Symbols: (HK: 1530) (NSDQ: AMGN) (NSDQ: BIIB)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital